Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0PU8T
|
||||
| Former ID |
DNCL001872
|
||||
| Drug Name |
E5555
|
||||
| Synonyms |
Atopaxar
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Eisai
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C29H38FN3O5
|
||||
| InChI |
InChI=1S/C29H38FN3O5/c1-7-37-23-15-19-16-33(28(31)24(19)25(30)27(23)38-8-2)17-22(34)18-13-20(29(3,4)5)26(35-6)21(14-18)32-9-11-36-12-10-32/h13-15,31H,7-12,16-17H2,1-6H3
|
||||
| InChIKey |
QWKAUGRRIXBIPO-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Thrombin receptor | Target Info | Antagonist | [531439], [531931] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| PANTHER Pathway | Angiogenesis | ||||
| Blood coagulation | |||||
| Pathway Interaction Database | PAR1-mediated thrombin signaling events | ||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| IL1 and megakaryotyces in obesity | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Hematopoietic Stem Cell Differentiation | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Thrombin signalling through proteinase activated receptors (PARs) | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| Ref 522232 | ClinicalTrials.gov (NCT00619164) A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome. U.S. National Institutes of Health. | ||||
| Ref 540648 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4048). | ||||
| Ref 531439 | Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53. | ||||
| Ref 531931 | Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program. J Thromb Thrombolysis. 2012 Jul;34(1):36-43. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.